Form 4: Precision BioSciences Executive Alan List Reports Stock Transactions
SEC Form 4 Filing
Alan List, Chief Medical Officer of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.
Summary
- Alan List, the Chief Medical Officer of Precision BioSciences, filed a Form 4 detailing changes in beneficial ownership.
- On April 26, 2024, List vested 868 shares of common stock from Restricted Stock Units (RSUs).
- On April 30, 2024, List sold 238 shares of common stock at an average price of $10.027 per share.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 24, 2022, to cover tax withholding obligations related to the RSU vesting.
- Following these transactions, List directly owns 3,796 shares of Precision BioSciences common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reflects routine transactions under a pre-existing plan to cover tax obligations. There is no indication of positive or negative sentiment towards the company's prospects.
Positives
- The transactions are part of a pre-arranged trading plan (Rule 10b5-1), suggesting they are not based on insider information.
- The sale was to cover tax obligations, which is a common and expected practice.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in the biotech industry, similar to how investors track filings from executives at companies like CRISPR Therapeutics or Editas Medicine.
- The use of 10b5-1 plans is common among executives to avoid accusations of insider trading, aligning with practices seen at comparable firms.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on stakeholders as they are routine and related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| June 7, 2021 | Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022 |
| March 24, 2022 | Rule 10b5-1 plan adopted |
| April 26, 2022 | RSUs vest in three substantially equal annual installments beginning on this date |
| February 13, 2024 | The Issuer effected a 1-for-30 reverse stock split |
| April 26, 2024 | Partial vesting and settlement of Restricted Stock Units |
| April 30, 2024 | Date of Form 4 filing and stock sale transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.